Patient First Architecture
DentiPay 3.0 | Investor Brief — The category validated at $70B+ in peak valuations. The dental vertical is still empty. The window is now.
Adaptive Market Intelligence LLC
RapidFire VC | April 2026
Confidential. Not for distribution without written consent of Adam Zuckerman, Founding Partner.
Founder's Note
Why This Company Exists
DentiPay didn't start as a business idea. It started as something Adam went through himself. The hard part wasn't the medicine — it was everything around it. Financing, approvals, timing, and a system that made no sense.
Adam comes from building capital systems: real estate, credit, structured finance — sectors where money moves efficiently because the infrastructure exists. Dentistry doesn't have that.
There was no intelligence system sitting between the patient, the provider, and the capital. Nothing to match the right people to the right financing at the right time. That is what DentiPay is. Not a lender. Not a brokerage. An intelligence layer that aligns patients, providers, and capital so the system actually works.
The Problem
Why Elective Healthcare Financing Is Broken
70%
Walk Away
Patients who need elective dental treatment never receive it — not due to lack of need or willingness to pay, but because the financing layer fails them.
$160B
U.S. Dental Market
Annual U.S. dental spend, including $25B in implant cases alone — yet the majority of cases never close.
$250
Consultation Fee Wall
Second opinions cost $180–$250 before any clinical work. Most patients cannot afford to even get a second opinion.
A patient walks in with a treatment plan ranging from $5,000 to $50,000. They are scared, uninformed, and handed a CareCredit application. Most are declined. Most leave and never come back. The financing layer is not a fixable inefficiency — it is a missing infrastructure layer.
The Four Failures of Today's System
Generic Financing Products
CareCredit, Cherry, Sunbit, GreenSky. Blind underwriting approves easy cases and declines everyone else. The borderline, immigrant, and underserved patient gets shut out.
No Patient Orientation
Patients make $25,000 decisions in the same room where they're told about surgical complications. No education layer, no triage, no human conversation.
No Alignment
Provider tries to close. Patient tries to escape. Financing company tries to underwrite. Three different motives, no shared infrastructure.
The Consultation Fee Wall
The American dental industry routinely loses cases to a WhatsApp call to another country — not because providers are less skilled, but because the wall is impassable.
Legacy Models
WHY DSOs CANNOT SOLVE THE FINANCING PROBLEM
DSOs were the last big bet on consolidating dentistry — Heartland, Aspen, Pacific, Smile Brands. Capital-intensive, acquisition-heavy, rollup-dependent. Fifteen years in, the market is full of stranded DSO equity and no DSO has solved the financing problem. The reason is structural.
Every legacy financing product — CareCredit, Cherry, Sunbit, GreenSky — was built on blind underwriting. Easy cases approve. Everyone else declines. Most providers have no second option when the first one fails. The conversation ends. The case dies. The patient walks out and never comes back.
The DSO consolidates the practice. It does not consolidate the patient relationship, the financing layer, or the capital infrastructure underneath the case. That is the layer that has never been built — until now.
The Deeper Structural Failure
Every legacy model requires the provider to also be the banker, the marketer, and the closer. None of those are clinical roles.
Providers are reverse archetypes — parking a Tesla in a patient's mouth without any means to drive off the lot.
Every minute a dentist spends chasing leads or negotiating with CareCredit is a minute they are not doing the work they trained for.
If the dentist is not the banker, who is? The platform. That is the Super PSO.
The Pivot
Introducing the Super PSO
The Patient Service Organization inverts the DSO. Where a DSO services the practice, the PSO services the patient. DentiPay 3.0 is the Super PSO — we do not buy practices, we do not roll up ownership. We own the patient relationship through the Concierge Portal, finance the case through SCOPE Cascade, and fund the provider's working capital through SCOPE Cascade.
Control the Product
SCOPE Cascade routes every patient to the right provider. Treatment routing is platform-controlled, not provider-controlled.
Control the Capital
We finance the patient case AND fund the provider's working capital. Both sides sit on SCOPE Cascade. CareCredit is not in the conversation.
Control the Destination
The patient enters, stays, and gets routed by the platform. Patient lifetime value compounds across implants, bridges, ortho, and recall — all on the same infrastructure.
Asset-light by design. Structurally locked-in by economics. DSOs need to acquire practices to grow. We need to onboard providers. DSOs carry rollup risk. We carry zero acquisition liability.
Our Roots
SCOPE Cascade: The Engine Behind the Platform
Signal-Capable Output Prediction Engine. A signal-based behavioral underwriting layer that sits above and before traditional bank underwriting. SCOPE does not compete with the lender — it qualifies the patient using behavioral signals that legacy credit underwriting cannot see, then routes them to the right capital partner at the right moment.
Approvals happen where CareCredit and blind underwriting decline. The borderline case becomes a closeable case.
$120M
Deployed in 2025
Capital deployed through the proven Cascade waterfall in 2025 alone.
220+
Lending Relationships
Active lending relationships powering multi-lender routing and approval optimization.
2 Yrs
Operational Data
Real approvals. Real funding. Real revenue. This is not a beta.
Part One
THE TESLA-IN-MOUTH PROBLEM | WHO CONTROLS THE PATIENT
Dentists have world-class technology and premium treatment plans, but no financing infrastructure to match. In many cases, the care needed is a $25K–$100K treatment plan, and the moment the patient hits the payment conversation, the momentum breaks. Patients need expensive care, then walk out when the payment plan does not work or CareCredit declines them. The case dies in the consultation room.
The Dental Industry Today
There is no platform underneath the provider. With 50,000–70,000 provider practices in the ecosystem, patients get declined by CareCredit and leave, the treatment plan stalls, and everyone loses — the provider, the manufacturer, and the patient.
When the case dies, the manufacturer loses downstream demand too, because the implant and treatment workflow never gets funded or completed.
Why Envista Cannot Build This Themselves
This is a structural conflict. Envista's sales force sells to dentists, not patients, and its roadmap is built around implants, not financing or trust. With roughly $520M in implant revenue and a $2.6B portfolio to protect, patient-first underwriting would sit awkwardly beside the core business.
Building a patient-first platform would mean competing with its own provider customers. They cannot build this.
Part Two
The Pivot: Patient First Architecture
DentiPay 3.0 inverts traditional telehealth. SCOPE Cascade processes the patient's financial qualification, triages the clinical need, and secures financing before the provider ever speaks to the patient. The provider's only job is to confirm the plan and accept the case. If the provider does not close, it rolls to the next provider. Round robin, just like a sales floor. The patient stays in the ecosystem. The provider is interchangeable. The patient is not.
SCOPE Cascade
Signal-based AI underwriting; 220+ lending relationships
Patient First Trust Portal
Human concierge, education, financing access
Provider Telehealth Layer
Pre-financed patients; 15–20 min closing calls
AI Behind the Curtain. Human at the Front.
AI Behind the Curtain
Every company in healthcare is racing to put AI in front of the patient. DentiPay 3.0 goes the other way. AI handles complexity invisibly. Humans handle trust. The differentiator is not whether AI is in the stack. The differentiator is where it sits and what it touches.
Human at the Front
A patient who needs $25,000 in dental work and is scared and stretched wants to talk to a human who understands their situation. The minute a patient realizes the front-line conversation is a machine, trust collapses. Trust is the conversion layer. Trust does not scale through chatbots.
This is not AI versus humans. This is AI multiplying humans.
SCOPE Cascade operates entirely behind the human layer. The patient experience is frictionless, from the moment they first engage to the moment they say yes in the chair. The manufacturer, for the first time, knows that patient before the provider ever sees them.
Part Four
The Proof: $70B+ in Category Validation
Nine platforms applying this exact model to adjacent verticals have generated over $70 billion in combined peak valuations. Every one took the customer relationship away from the provider, made the provider a backend fulfillment resource, and controlled the consumer's wallet and trust at the platform level.
Part Five
Proof of Execution: What Is Already Built
01
DentiPay Is Live
Operating with hundreds of providers for over two years. Not a beta. Not a concept. Real revenue, real approvals, real funding.
02
SCOPE Cascade Is Deployed
SCOPE Cascade deployed — $120M+ in annual paper. 220+ lending relationships. Proprietary IP.
03
TrustLock Executed
Master License and Platform Build Agreement signed March 26, 2026 with Abundance Group Holdings. Jay Conner's $52M/year private financing volume routing through SCOPE Cascade.
04
Strategic Advisors Signed
Neil Sahota (UN AI Advisor, IBM Watson pioneer) signed April 17, 2026. Emilio Arguello confirmed face-to-face meetings with Envista/Nobel Biocare, Straumann Group, and two additional manufacturer targets.
05
Vertical Portfolio Expanding
DentiPay (dental), CosmetiPay (cosmetic/elective), TrustLock (trust/estate capital), DentiPay Labs (AI development). SCOPE Cascade is sector-agnostic — platform built once, verticals unlimited.
The Competitive Landscape
No existing telehealth platform uses the DentiPay 3.0 provider-incentive model. DentiPay 3.0 is the only platform where the provider's time investment converts directly into a financed patient in the chair.
Hims & Hers
Wins in async telehealth verticals. Architecturally cannot solve dental: a $25,000 decision at a physical chair is not a chatbot conversation.
Teladoc
$23–28/visit. Platform keeps ~70%. Provider is interchangeable.
Denteractive
Provider PAYS the platform. Zero ROI on time invested.
TeleDentists
Paid per async review. No chair conversion.
DentiPay 3.0
Provider donates one consult. Receives a financed patient worth $3,000–$6,000+. Incomparable ROI.
Part Six
Economics: Two-Sided Capital Deployment
DentiPay 3.0 is a capital deployment business — two parallel flows of capital, both clipped at a 7% blended platform margin.
$3.75B
Patient Financing (Year 5)
$2.5B
Provider Capital (Year 5)
$537.5M
Platform Revenue (Year 5)
$100M
Membership Revenue (1M members × $100/yr)
The same patient finances a bridge in Year 1, an implant in Year 2, an ortho referral in Year 3. Revenue per patient grows year over year on the same platform infrastructure.
Part Seven
The Window: Why Now
First-mover position in embedded patient-first financing inside dental is a once-in-a-generation opportunity. The category has already been validated at $3.9 billion in combined exits within adjacent embedded financing verticals alone — Open Lending at $1.7B, Acima at $1.65B, Cross River at $620M. None of these touched dental.
Manufacturer Partnerships
Emilio Arguello has confirmed face-to-face meetings with Envista/Nobel Biocare, Straumann Group, and two additional manufacturer targets in the current cycle.
The Novo Nordisk Precedent
Novo Nordisk partnered with Hims because Hims owns a patient relationship at scale that Novo's entire sales force cannot reach. Envista/Nobel faces the identical ceiling. The question is binary: be the Novo Nordisk of dental implants, or watch the market route around you.
The Investor Opportunity
SCOPE Cascade uses behavioral financing on a national lending network — a fundamentally superior architecture to the blind underwriting models that have already generated billion-dollar exits in adjacent verticals. The floor should be higher.
Executive Summary
The Five-Line Investor Take
1
The Thesis
Super PSO. We control the product (case routing), the capital (patient and provider financing), and the destination (where the patient lands). Three forms of control no incumbent has.
2
The Deployment
Year 5 target: $3.75B in patient financing + $2.5B in provider working capital = $6.25B in annual capital deployed through SCOPE Cascade. 1M financed patients. 5,000 funded dentists.
3
The Moat
SCOPE Cascade is the proprietary behavioral underwriting engine. 220+ lending relationships. $120M+ in annual paper already flowing today. The platform that approves where CareCredit declines.
4
The Portal
Concierge entry at $100/yr. Human-led, telephony-driven education-to-conversion engine. Anti-AI by design. 15% conservative conversion to financed case.
5
The Window
DentiPay is live. TrustLock Master Agreement executed March 26, 2026. Neil Sahota signed April 17, 2026. Envista/Nobel, Straumann, and two additional manufacturer targets in live partnership conversations in the current cycle.
"We are not the Prime membership. We are the warehouse, the inventory, and the truck."
Leadership
The Operators Behind the Platform
Adam Zuckerman — FOUNDING PARTNER | ARCHITECT OF SCOPE CASCADE
35+ years across capital markets, real estate, structured finance, and venture. Founder of Adaptive Market Intelligence and RapidFire VC. Architect of SCOPE Cascade, the signal-capable behavioral underwriting engine that powers $120M+ in annual deployed paper today. Built the patient-first thesis from lived experience, not theory. Owns the Super PSO playbook, the vertical expansion roadmap across DentiPay, CosmetiPay, TrustLock, and DentiPay Labs, and the capital deployment infrastructure that scales every vertical. Operator with no patience for slow money.
Dr. Emilio Arguello — Dental Strategy & Manufacturer Relationships
20+ years of dental industry C-suite access at the manufacturer, distributor, and KOL level. Former senior leadership across implant and restorative manufacturers. Direct relationships across Envista/Nobel Biocare, Straumann Group, and the global dental innovation network. Leads DentiPay's manufacturer strategy and runs point on every Tier 1 partnership conversation. Face-to-face meetings already confirmed in the current cycle. The patient access ceiling problem is the framework on the table. Emilio is the one who walks it through the door.
Neil Sahota — Chief AI Officer
United Nations AI Advisor and one of the original architects of IBM Watson. Author of Own the AI Revolution (McGraw-Hill). Keynote across 30+ countries, advisor to Fortune 500 boards and sovereign AI programs. Brings institutional gravity, AI validation, and strategic capital reach to DentiPay 3.0. The credibility anchor that opens doors most platforms never see. Strategic Advisory Agreement signed April 17, 2026.
The Full Leadership Team
Jay Oku
CHIEF BUSINESS OFFICER | RAPIDFIRE VC
Strategic operator on DentiPay 3.0 architecture. Originator of the coordinator integration framework and the pre-qualification model that drives concierge-to-financed-case conversion. Runs investor qualification, partnership coordination, and pipeline cultivation across the Tier 1 capital track. The structural mind behind how the platform's two-sided capital flows interconnect.
Colin Matthew
CHIEF FUNDING OFFICER
CFO of the Adaptive Market Intelligence platform. Owns fee structure, capital allocation, and financial infrastructure across DentiPay, CosmetiPay, TrustLock, and DentiPay Labs. Runs the recurring revenue engine that funds platform expansion. Architect of the 7% blended platform margin model and the Year 5 economics that map to $537.5M annual platform revenue.
NUTTALYA Reussi
Co-Founder, Chief Operating Officer
COO of Adaptive Market Intelligence. Owns platform operations, brand architecture, and the coordinator layer that translates SCOPE Cascade routing into patient experience. Runs the DentiPay 3.0 operational stack across all verticals. The operational backbone that turns the patient-first thesis into a working concierge engine, end to end.
Peter Clayton
Principal Systems Architect
Owns the technical architecture for SCOPE Cascade deployment. Bridges the signal-capable behavioral underwriting engine to the DentiPay Patient First portal and the Provider Telehealth Layer. Designs the integration logic that makes the multi-bank waterfall, real-time qualification, and concierge-handoff layer all run as a single seamless system. The engineering spine of the platform.
The Window Is Now
Whoever controls the patient controls the market. DentiPay 3.0 is the first platform to do this in dental with behavioral financing on a national lending network.
Platform Is Live
Hundreds of providers. $120M+ annual paper flowing. SCOPE Cascade operational. TrustLock executed. Neil Sahota on board.
Partnerships in Motion
Envista/Nobel Biocare, Straumann Group, and two additional manufacturer targets in live conversations in the current cycle.
Year 5 Target
$537.5M annual platform revenue. $6.25B in capital deployed. 1M financed patients. 5,000 funded dentists.
Adam Zuckerman | Founding Partner
Adaptive Market Intelligence LLC | RapidFire VC
[email protected] | (213) 310-0233 | www.rapidfirevc.com
Confidential. Not for distribution without written consent of Adam Zuckerman, Founding Partner.
Video Library